Plus Therapeutics Inc

Plus Therapeutics announced it will present two posters on its ReSPECT-LM clinical program and CNSide diagnostic platform at the 2026 SNO/ASCO CNS Metastases Conference in Boston from August 13 to 15. The company and its subsidiary CNSide Diagnostics will also host a sponsored symposium on August 13 titled “Redefining the Management of Leptomeningeal Metastases: Integrating Diagnostics, Molecular Insights, and Emerging Therapies.” The ReSPECT-LM poster will feature pharmacokinetic and pharmacodynamic data on rhenium obisbemeda with emerging repeated dosing results, while the CNSide poster will present a cost-of-care analysis on earlier detection of leptomeningeal metastases. Plus Therapeutics also plans to introduce its new corporate identity, Cerenome, at the meeting, ahead of its official name change and Nasdaq ticker switch to CNSY effective August 3, 2026.

CNSide Diagnostics, a subsidiary of Plus Therapeutics, has signed a regional coverage agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people in Ohio and Kentucky for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration assay. This latest agreement brings total contracted coverage for the CNSide assay to approximately 127 million people. The assay supports rapid diagnoses, treatment monitoring, and guidance for patients with leptomeningeal metastases, and has been used in over 11,000 tests at more than 120 U.S. cancer institutions since 2020, demonstrating 92% sensitivity and 95% specificity while influencing treatment decisions in 90% of cases.

Plus Therapeutics and Genomic Testing Cooperative announced a collaboration to integrate next-generation sequencing technology into the CNSide cerebrospinal fluid assay platform. The partnership aims to enable comprehensive DNA and RNA profiling of hundreds of clinically relevant biomarkers from a single CSF specimen, extending CNSide beyond CTC enumeration into guideline-recognized DNA and tumor-derived DNA analysis. The CNSide CSF Tumor Cell Enumeration test received a dedicated AMA PLA code effective July 1, 2026, and the CNSide CLIA laboratory is enrolled with Medicare, with commercial payer agreements covering approximately 126 million U.S. lives. A recent health-economic analysis associated CNSide-enabled earlier diagnosis of leptomeningeal metastases with an approximately 40% reduction in overall LM-related healthcare costs. The collaboration supports Plus Therapeutics' three-pillar CNS oncology strategy, which includes targeted radiotherapeutics led by REYOBIQ, precision diagnostics anchored by CNSide, and AI-enabled data analytics through a partnership with Ephemeral Technologies.

Plus Therapeutics will rebrand as Cerenome and begin trading on Nasdaq under the ticker CNSY on August 3, 2026. The company reaffirmed its 2026 milestones and reported that contracted insurance coverage for its CNSide diagnostics platform has grown to approximately 126 million covered lives, up from around 67 million at the start of the year, with a target of over 150 million by year-end. CNSide performed 232 tumor cell enumeration tests year-to-date, including a record 72 in June, and is targeting an annualized run rate of 1,250 tests by the close of 2026. For its lead therapeutic candidate REYOBIQ, 31 of 34 planned patients have been enrolled in the Phase 2 ReSPECT-GBM trial, while the Phase 2 ReSPECT-LM study has enrolled about one-third of its target population. The company also expects to dose the first patient in the ReSPECT-PBC pediatric brain cancer trial in the third quarter of 2026.

Plus Therapeutics announced that its wholly owned subsidiary CNSide Diagnostics has signed a national agreement with Elevance Health for the CNSide cerebrospinal fluid tumor cell enumeration assay, effective May 1, 2026. The CNSide assay is used to detect leptomeningeal metastases in patients with carcinomas and melanomas, and has demonstrated 92% sensitivity and 95% specificity in over 11,000 tests performed across 120 U.S. cancer institutions since 2020. Through the contract with Elevance, the test is expected to add 45.5 million covered lives, bringing total coverage to 126 million people across the United States.